Another clinical trial has demonstrated significantly improved outcomes in patients with high-risk neuroblastoma after the combined treatment with ch14.18 antibody to isotretinoin and IL2 or granulocyte macrophage-colony stimulating factor (GM-CSF) [95]. The gene discussed is IL2; the disease is neuroblastoma.